{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"475"}],"units":"Participants"}],"description":"An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued treatment due to an AE was assessed.","groups":[{"description":"Participants received pembrolizumab 10 mg/kg intravenously (IV) over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. Per protocol participants were presented by treatment received in the single arm study.","id":"OG000","title":"Pembrolizumab (MK-3475) 10 mg/kg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The analysis population consisted of all allocated participants who received at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"Up to approximately 25 months","title":"Number of Participants Who Discontinued From Study Treatment Due to an AE","type":"SECONDARY","unitOfMeasure":"Participants"}